Avrobio (Avrobio) EPS (Basic) : $0.28 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Avrobio EPS (Basic)?

Avrobio's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-0.20. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.28.

Avrobio's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.27.

Avrobio's EPS without NRI for the three months ended in Dec. 2023 was $-0.20. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -1.18.

During the past 3 years, the average EPS without NRI Growth Rate was 23.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Avrobio's highest 3-Year average EPS without NRI Growth Rate was 23.00% per year. The lowest was -55.20% per year. And the median was 3.10% per year.

Avrobio EPS (Basic) Historical Data

The historical data trend for Avrobio's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avrobio EPS (Basic) Chart

Avrobio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-2.66

-3.31

-2.78

-2.42

0.27

Avrobio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-0.57	-0.57	1.53	-0.48	-0.20

Avrobio EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Avrobio's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(12.157	-	0)	/	44.327
	=	0.27

Avrobio's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.785	-	0)	/	44.604
	=	-0.20

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.28

Avrobio (NAS:AVRO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Avrobio EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Avrobio's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Avrobio (Avrobio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avrobio Inc (NAS:AVRO) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Technology Square, Sixth Floor, Cambridge, MA, USA, 02139

Website

https://www.avrobio.com

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.

Executives

Azadeh Golipour	officer: Chief Technology Officer	ONE KENDALL SQUARE, BLD. 300 - SUITE 201, CAMBRIDGE MA 02139
Essra Ridha	officer: Chief Medical Officer	C/O AVROBIO, INC., ONE KENDALL SQUARE, BLDG 300 - SUITE 201, CAMBRIDGE MA 02139
Philip J. Vickers	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Christopher Mason	officer: Chief Scientific Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Phillip B. Donenberg	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Diana Escolar	officer: Chief Medical Officer	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Gail M Farfel	director	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Deanna M Petersen	officer: Chief Business Officer	45 FIRST AVENUE, WALTHAM MA 02451
Geoffrey Mackay	director, officer: See Remarks	C/O AVROBIO, INC., ONE KENDALL SQ, BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Christopher Paige	director	C/O AVROBIO INC, ONE KENDALL SQ, BLDG 300, STE 201, CAMBRIDGE MA 02139
Atlas Venture Fund X, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, Llc	other: See Remarks	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, L.p.	other: See Remarks	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund I, L.p.	other: See Remarks	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Bruce Booth	director	890 WINTER STREET, SUITE 320, WALTHAM MA 02451